Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study
Publication
, Conference
Clowse, MEB; Houssiau, F; Petri, MA; Kilgallen, B; Kalunian, K; Strand, V; Bongardt, S; Gordon, C; Wallace, DJ
Published in: ARTHRITIS AND RHEUMATISM
October 1, 2013
Duke Scholars
Published In
ARTHRITIS AND RHEUMATISM
EISSN
1529-0131
ISSN
0004-3591
Publication Date
October 1, 2013
Volume
65
Start / End Page
S737 / S738
Location
San Diego, CA
Publisher
WILEY-BLACKWELL
Conference Name
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals
Related Subject Headings
- Arthritis & Rheumatology
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Clowse, M. E. B., Houssiau, F., Petri, M. A., Kilgallen, B., Kalunian, K., Strand, V., … Wallace, D. J. (2013). Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study. In ARTHRITIS AND RHEUMATISM (Vol. 65, pp. S737–S738). San Diego, CA: WILEY-BLACKWELL.
Clowse, Megan E. B., Frederic Houssiau, Michelle A. Petri, Brian Kilgallen, Kenneth Kalunian, Vibeke Strand, Sabine Bongardt, Caroline Gordon, and Daniel J. Wallace. “Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study.” In ARTHRITIS AND RHEUMATISM, 65:S737–38. WILEY-BLACKWELL, 2013.
Clowse MEB, Houssiau F, Petri MA, Kilgallen B, Kalunian K, Strand V, et al. Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study. In: ARTHRITIS AND RHEUMATISM. WILEY-BLACKWELL; 2013. p. S737–8.
Clowse, Megan E. B., et al. “Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study.” ARTHRITIS AND RHEUMATISM, vol. 65, WILEY-BLACKWELL, 2013, pp. S737–38.
Clowse MEB, Houssiau F, Petri MA, Kilgallen B, Kalunian K, Strand V, Bongardt S, Gordon C, Wallace DJ. Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study. ARTHRITIS AND RHEUMATISM. WILEY-BLACKWELL; 2013. p. S737–S738.
Published In
ARTHRITIS AND RHEUMATISM
EISSN
1529-0131
ISSN
0004-3591
Publication Date
October 1, 2013
Volume
65
Start / End Page
S737 / S738
Location
San Diego, CA
Publisher
WILEY-BLACKWELL
Conference Name
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals
Related Subject Headings
- Arthritis & Rheumatology
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences